title: Peripheral T-lymphocyte subsets in patients treated with Rituximab-Chlorambucil combination therapy for indolent NHL.
authors.forename: D
authors.initials: D
authors.lastname: Laszlo
authors.forename: S
authors.initials: S
authors.lastname: Bassi
authors.forename: G
authors.initials: G
authors.lastname: Andreola
authors.forename: A
authors.initials: A
authors.lastname: Agazzi
authors.forename: P
authors.initials: P
authors.lastname: Antoniotti
authors.forename: R
authors.initials: R
authors.lastname: Balzano
authors.forename: P
authors.initials: P
authors.lastname: Mancuso
authors.forename: F
authors.initials: F
authors.lastname: Bertolini
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes; D018414:CD8-Positive T-Lymphocytes; D002699:Chlorambucil / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007694:Killer Cells, Natural; D018655:Lymphocyte Count; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab; D016176:T-Lymphocyte Subsets / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D002699:Chlorambucil; D000069283:Rituximab